# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Bob Marley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML027-SYN
- Date: 2026-06-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Desmond Clarke, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Toenail biopsy result and surgical oncology consultation. **S**

## History of present illness

Mr. Marley returns nine days after his first visit. The clinic's dermatologist examined the nail with dermoscopy two days after that visit, found a band with irregular lines of varying color and spacing and pigment on the nail fold, and took a full-thickness excisional biopsy of the nail matrix under a digital block. The biopsy shows acral lentiginous melanoma, 0.8 mm thick, not ulcerated. The biopsy site has healed under the dressing; he has needed no pain medicine. He has no lumps in the groin or behind the knee, no cough, headache, or weight loss. Dr. Mbeki-Rowe of surgical oncology saw him this morning and went through the choices for surgery with him at length. He said that his faith, his music and his football all matter to him in this decision, and that he would like to keep the toe if that can be done without lowering his chance of cure. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Diagnosis | Acral lentiginous melanoma of the right great toe nail unit, Breslow 0.8 mm, not ulcerated, mitotic rate 1 per mm2 |
| Clinical stage | IB (cT1b N0 M0); no symptoms of spread |
| Biopsy site | Healing; no pain medicine needed |
| Coordination | Surgical oncology seen this morning; surgery planned in two weeks |
| What matters to him | His faith, his music and his football; keeping the toe if that is safe |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight loss, fever, or night sweats |
| Respiratory | Negative | No cough or breathlessness |
| Neurological | Negative | No headache or weakness |
| Integumentary | Negative | No other new or changing spots, bands, or sores |
| Hematologic and lymphatic | Negative | No lumps in the groin or behind the knee |
| Psychiatric | Positive | Worried about the operation and touring; PHQ-9 4, GAD-7 6; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 66.2 kg; BMI 22.9 kg/m². All vital signs are synthetic.

PHQ-9: 4; GAD-7: 6. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 70; weight 66.2 kg |
| Right great toe | Biopsy site healing over the proximal nail; the remaining nail plate shows the distal part of the brown-black band; pigment on the proximal nail fold; no nodule or ulcer |
| Lymph nodes | No right popliteal or inguinal nodes; no left inguinal, axillary, or cervical nodes |
| Skin and nails | Whole skin examined, including the scalp, palms, soles, between the toes, and all nails: no other suspicious lesion |
| Abdomen | Soft; liver not enlarged |
| Psychiatric | Calm, thoughtful; asks careful questions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acral lentiginous melanoma of the right great toe nail unit, clinical stage IB (cT1b N0 M0)** (C43.71). A thin acral melanoma of the nail unit, diagnosed nine days after he first came in, because a band that had not grown out and pigment on the nail fold were biopsied rather than called a bruise. Acral melanoma is the most common melanoma in people with darker skin and is not caused by the sun. At 0.8 mm it is T1b: no scans or blood tests are needed, and a sentinel lymph node biopsy is offered because the chance of a positive node is about 5 to 10 percent. Dr. Mbeki-Rowe set out the two surgical choices: amputation of the toe at the interphalangeal joint, or digit-sparing excision of the whole nail unit down to the bone with a skin graft. For a melanoma this thin, digit-sparing excision is an accepted choice with similar survival in published series, at the cost of a higher chance of a local recurrence that would then need amputation. With his values in view, he chose digit-sparing excision with a sentinel node biopsy, and agreed in advance that amputation would be the next step if the margins were involved or the melanoma proved thicker. **S**
   - Digit-sparing excision of the nail unit with a full-thickness skin graft and right inguinal sentinel node biopsy with Dr. Mbeki-Rowe in two weeks, after lymphoscintigraphy the same morning.
   - No staging scans or LDH.
   - No blood tests needed before surgery for a healthy man of 32.
   - A written summary of the decision given to him.
2. **Dark band in the right great toenail with pigment on the nail fold** (L60.8). Explained by the biopsy; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Biopsy pathology: Breslow thickness, ulceration, mitotic rate, margins, and microsatellites | At diagnosis | Up to date | 0.8 mm, not ulcerated, mitotic rate 1 per mm2, no lymphovascular or perineural invasion, no microsatellites; melanoma in situ at the lateral edges |
| Examination | Dermoscopy of the nail | At presentation with a pigmented nail band | Up to date | By the dermatologist two days after the first visit: irregular lines and pigment on the nail fold |
| Examination | Full skin and nail examination, including the scalp, palms, soles, between the toes, and all nails | At diagnosis, then at each surveillance visit | Deferred | A deviation: the dermatologist examined the hands, feet and nails at the biopsy visit, but a full skin examination at diagnosis was not recorded. Dr. Clarke examined the whole skin today and found no other suspicious lesion, so no harm resulted. Corrective action: a yearly full skin examination by dermatology is booked, and the full examination is part of each surveillance visit |
| Examination | Examination of the lymph node basins (right popliteal and inguinal) and the scar | At diagnosis, then at each surveillance visit | Completed today | No palpable nodes |
| Imaging | Imaging (CT, PET, or ultrasound) and LDH | Not routine for stage I to II without symptoms | Not indicated | Clinical stage IB without symptoms; scans and LDH would not change management |
| Referral | Sentinel lymph node biopsy | Discussed and offered for T1b melanoma | Ordered | Accepted; with the excision in two weeks, after lymphoscintigraphy |
| Referral | Surgical oncology | At diagnosis of invasive melanoma | Completed today | Seen this morning; recommendations in the consultation note |
| Self-management | Shared decision on the extent of surgery | Before definitive surgery | Completed today | Amputation and digit-sparing excision explained with their outcomes; he chose digit-sparing excision; written summary given |
| Laboratory | Germline genetic testing | Only with several primary melanomas or a strong family history of melanoma or pancreatic cancer | Not indicated | A single primary melanoma; no criterion met |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis | Completed today | PHQ-9 4 and GAD-7 6; no thoughts of self-harm |

## Goal progress

- Tissue diagnosis within two weeks of presentation. Outcome by 2026-06-17: Dermoscopy and nail matrix biopsy two days after presentation; diagnosis explained on the ninth day. **S**
- Definitive surgery with clear margins and lymph node staging within four weeks of diagnosis, by the approach he chose. In progress; target 2026-07-15. **S**
- Walk, run, and play football normally within four months of surgery. In progress; target 2026-10-19. **S**
- Monthly skin and nail self-examination, including the palms, soles, between the toes and all nails. In progress; target 2026-10-19. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous, Version 3.2026 (2026), National Comprehensive Cancer Network
- Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019;80(1):208-250 (2019), American Academy of Dermatology
- Gershenwald JE, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67(6):472-492 (2017), American Cancer Society (CA: A Cancer Journal for Clinicians)
- Wong SL, et al. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018;36(4):399-413 (2018), American Society of Clinical Oncology and Society of Surgical Oncology
- Chouquet L, et al. Reconstruction After Wide Excision of the Nail Apparatus in the Treatment of Melanoma: A Systematic Literature Review. J Clin Med 2025;14(17):5932 (2025), Journal of Clinical Medicine
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Surgery in two weeks with Dr. Mbeki-Rowe. Review two weeks after surgery with the final pathology. Call for a lump in the groin, or for redness or discharge at the biopsy site. **S**
- Next scheduled visit 2026-07-15: review two weeks after digit-sparing excision and sentinel node biopsy: final pathology and stage, graft care, and the surveillance plan. **S**
